Gemcitabine (1000 mg/m^2)

DRUG2 trials

Sponsors

Prestige Biopharma Limited, AntiCancer Research Jamaica

Conditions

Metastatic Triple-negative Breast CancerPancreatic CancerTriple Negative Breast Cancer

Phase 1

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Active, not recruitingNCT05141149

Prestige Biopharma LimitedPancreatic Cancer

Start: 2023-06-05End: 2026-12-01Target: 80Updated: 2026-07-27

Phase 2

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Not yet recruitingNCT07528768

AntiCancer Research JamaicaMetastatic Triple-negative Breast Cancer, Triple Negative Breast Cancer

Start: 2026-06-01End: 2034-06-01Target: 750Updated: 2026-04-14

Related Papers

First-in-human phase 1/2a study of PBP1510 (anti-PAUF mAb) in advanced/metastatic pancreatic adenocarcinoma: Safety results from early combination cohorts.

Journal of Clinical Oncology2025-05-28

Abstract CT061: Preliminary safety results from the first-in-human phase 1/2a study of PBP1510 (anti-PAUF mAb) in advanced/metastatic pancreatic adenocarcinoma

Cancer Research2025-04-25

PBP1510, a novel monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF): Phase 1/2a monotherapy and combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.

Journal of Clinical Oncology2024-06-01

Abstract CT083: A first-in-human phase 1/2a study of a novel anti-PAUF monoclonal antibody PBP1510 in patients with advanced/metastatic pancreatic cancer

Cancer Research2024-04-05